Treatment of unresectable stage III non-small cell lung cancer for patients who are under-represented in clinical trials

被引：3

作者：

Bortolot, Martina ^{[1
,2
]}

Cortiula, Francesco ^{[2
,3
]}

Fasola, Gianpiero ^{[2
]}

De Ruysscher, Dirk ^{[3
]}

Naidoo, Jarushka ^{[4
,5
,6
]}

Hendriks, Lizza E. L. ^{[7
]}

机构：

[1] Univ Udine, Dept Med DAME, Udine, Italy

[2] Univ Hosp Udine, Dept Oncol, Piazzale Santa Maria Misericordia, I-33100 Udine, Italy

[3] Maastricht Univ, GROW Sch Oncol & Reprod, Dept Radiat Oncol Maastro, Med Ctr, Maastricht, Netherlands

[4] Beaumont Hosp, Dublin, Ireland

[5] RCSI Univ Hlth Sci, Dublin, Ireland

[6] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[7] Maastricht Univ, GROW Sch Oncol & Reprod, Dept Pulm Dis, Med Ctr, Maastricht, Netherlands

来源：

CANCER TREATMENT REVIEWS | 2024年 / 129卷

关键词：

NSCLC; Unresectable stage III; Special populations; Elderly; Frail; Comorbidities; PREDICTING RADIATION PNEUMONITIS; REAL-WORLD DATA; CONCURRENT CHEMORADIOTHERAPY; ELDERLY-PATIENTS; OLDER PATIENTS; RADIOTHERAPY; THERAPY; DURVALUMAB; NSCLC; CHEMORADIATION;

D O I：

10.1016/j.ctrv.2024.102797

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Concurrent chemoradiotherapy (cCRT) followed by one year of consolidation durvalumab is the current standard-of-care for patients with unresectable stage III non-small cell lung cancer (NSCLC), of good functional status. However, cCRT and consolidation durvalumab may be challenging to administer for selected patient populations underrepresented or even excluded in clinical trials: older and/or frail patients; those with cardiovascular or respiratory comorbidities in which treatment-related adverse events may be higher, and patients with pre-existing autoimmune disorders for whom immunotherapy use is controversial. In this narrative review, we discuss the current evidence, challenges, ongoing clinical trials and potential future treatment scenarios in relevant subgroups of patients with locally advanced NSCLC, who are underrepresented in clinical trials.

引用

页数：9

共 98 条

[71] Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era [J].

Passiglia, Francesco ;

Leone, Gianmarco ;

Olmetto, Emanuela ;

Delcuratolo, Marco Donatello ;

Tabbo, Fabrizio ;

Reale, Maria Lucia ;

Bertaglia, Valentina ;

Consito, Lorena ;

Bironzo, Paolo ;

Capelletto, Enrica ;

Novello, Silvia .

LUNG CANCER, 2021, 157 :85-91

[72] Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14) [J].

Peters, Solange ;

Felip, Enriqueta ;

Dafni, Urania ;

Tufman, Amanda ;

Guckenberger, Matthias ;

Alvarez, Ruth ;

Nadal, Ernest ;

Becker, Annemarie ;

Vees, Hansjorg ;

Pless, Miklos ;

Martinez-Marti, Alex ;

Lambrecht, Maarten ;

Andratschke, Nicolaus ;

Tsourti, Zoi ;

Piguet, Anne-Christine ;

Roschitzki-Voser, Heidi ;

Gasca-Ruchti, Adrian ;

Vansteenkiste, Johan ;

Stahel, Rolf A. ;

De Ruysscher, Dirk .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (02) :278-288

[73] Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Postmus, P. E. ;

Kerr, K. M. ;

Oudkerk, M. ;

Senan, S. ;

Waller, D. A. ;

Vansteenkiste, J. ;

Escriu, C. ;

Peters, S. .

ANNALS OF ONCOLOGY, 2017, 28 :1-21

[74] Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study [J].

Rancati, T ;

Ceresoli, GL ;

Gagliardi, G ;

Schipani, S ;

Cattaneo, GM .

RADIOTHERAPY AND ONCOLOGY, 2003, 67 (03) :275-283

[75] Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians [J].

Raschi, Emanuel ;

Rossi, Simone ;

De Giglio, Andrea ;

Fusaroli, Michele ;

Burgazzi, Flavio ;

Rinaldi, Rita ;

Potena, Luciano .

DRUG SAFETY, 2023, 46 (09) :819-833

[76] Age and Comorbidity Considerations Related to Radiotherapy and Chemotherapy Administration [J].

Rodrigues, George ;

Sanatani, Michael .

SEMINARS IN RADIATION ONCOLOGY, 2012, 22 (04) :277-283

[77] The Impact of the Availability of Immunotherapy on Patterns of Care in Stage III NSCLC: A Dutch Multicenter Analysis [J].

Ronden, Merle I. ;

Bahce, Idris ;

Claessens, Niels J. M. ;

Barlo, Nicole ;

Dahele, Max R. ;

Daniels, Johannes M. A. ;

Tissing-Tan, Caroline ;

Hekma, Edo ;

Hashemi, Sayed M. S. ;

van der Wel, Antoinet ;

Spoelstra, Femke O. B. ;

Verbakel, Wilko F. A. R. ;

Tiemessen, Marian A. ;

van Laren, Marjolein ;

Becker, Annemarie ;

Tarasevych, Svitlana ;

Haasbeek, Cornelis J. A. ;

van den Brink, Karen Maassen ;

Dickhoff, Chris ;

Senan, Suresh .

JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (07)

[78] Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study [J].

Ruysscher, D. De ;

Botterweck, A. ;

Dirx, M. ;

Pijls-Johannesma, M. ;

Wanders, R. ;

Hochstenbag, M. ;

Dingemans, A. -M. C. ;

Bootsma, G. ;

Geraedts, W. ;

Simons, J. ;

Pitz, C. ;

Lambin, P. .

ANNALS OF ONCOLOGY, 2009, 20 (01) :98-102

[79]

SABR UK Consortium, 2019, UK SABR Consortium Guidance

[80] The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly [J].

Schild, SE ;

Stella, PJ ;

Geyer, SM ;

Bonner, JA ;

McGinnis, WL ;

Mailliard, JA ;

Brindle, J ;

Jatoi, A ;

Jett, JR .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) :3201-3206

← 1 2 3 4 5 6 7 8 9 10 →